Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CSK | P41240 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203321 | 0.86 | CES2 (0.64) | CES2CES1PARP1LMNAPBRM1 | |
| SCHEMBL28012106 | 0.84 | SLC9A1 (0.42) | CES2CES1PREPPARP1LCK | |
| SCHEMBL28267101 | 0.84 | CES2 (0.61) | CES2CES1PARP1LMNAPBRM1 | |
| Hydrochloric Acid SCHEMBL5053757 | 0.84 | CES2 (0.61) | CES2CES1PARP1LMNAPBRM1 | |
| SCHEMBL1613338 | 0.84 | MMP2 (0.43) | PARP1GAATDP1JAK1 | |
| SCHEMBL283962 | 0.83 | CES2 (0.54) | CES2CES1PREPCRBNLMNA | |
| Hydrochloric Acid SCHEMBL7276404 | 0.81 | CES2 (0.52) | CES2CES1PREPCRBNLMNA | |
| SCHEMBL4089662 | 0.81 | CES2 (0.52) | CES2CES1PREPCRBNLMNA | |
| SCHEMBL14454258 | 0.81 | CES2 (0.52) | CES2CES1PREPCRBNLMNA | |
| SCHEMBL7952512 | 0.78 | CES2 (0.43) | CES2CES1PREPCRBNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744379-B | A kind of quianzolinones and its synthetic method | 三峡大学 | 2017-10-27 | — | — | CN | claimed |
| CN-104557738-A | Green synthesis method of 4(3H)-quinazolinone | UNIV HUNAN | 2015-04-29 | — | — | CN | claimed |
| CN-104447580-A | Method for synthesizing quinazolone compounds | UNIV HUNAN | 2015-03-25 | — | — | CN | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3947368-B1 | BIFUNCTIONAL COMPOUNDS COMPRISING A CDK2/5 LIGAND, A LINKER AND A E3 UBIQUITIN LIGASE BINDING DEGRON FOR THE TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025073583-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-04-10 | — | — | WO | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-118791498-A | Tetracyclic compound, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| CN-115650924-B | Green synthesis method of quinazolinone | 山东华泰新材料技术研发有限公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-1751118-A1 | PYRIMIDINES FOR USE AS PLK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005113515-A1 | PYRIMIDINES FOR USE AS PLK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261295-A1 | 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1598343-A1 | 2-Arylaminopyrimidine derivatives as PLK inhibitors | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-5030727-A | Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0263523-A2 | Process for the preparation of thiazolo [2,3-b] quinazolones | BASF Aktiengesellschaft (DE) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261295-A1 | 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents | MKI67, CCNY, CCNO | CES2 3943/4885CES1 3021/4885PREP 3188/4885 |
| US-12466809-B2 | CDK2/5 degraders and uses thereof | CDK2, CDK5, CDK5R1 | CES2 3511/4885CES1 3056/4885PREP 573/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | CES2 3755/4885CES1 3157/4885PREP 684/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CES2 3755/4885CES1 3157/4885PREP 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.